Protherics reiterated by Jefferies at buy

Jefferies & Co., Inc. analyst Robin Campbell reiterated Protherics plc at a buy and updated the price target to 170p from 140p. According to the analyst, the company is making progress where it should. However, Protherics must convince investors that it can successfully bring Voraxaze to the market. Shares of the Runcorn, U.K.-based biopharmaceutical company were down 3.50p, or 3.95% at 85.00p on volume of 712,729 shares versus the three-month running average of 368,981 shares. (London: PTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.